

EPL

| |
|--------------|
| 1 |
| \leftarrow |
| |

| EPLL IN |
|------------|
| 316 |
| 60.9 / 0.7 |
| 206 / 147 |
| 15/21/10 |
| 103 |
| |

Financials & Valuations (INR b)

| Y/E Mar | 2023 | 2024E | 2025E |
|---------------|------|-------|-------|
| Sales | 36.9 | 43.1 | 46.9 |
| EBITDA | 5.8 | 7.5 | 8.5 |
| PAT | 2.3 | 2.9 | 3.5 |
| EBITDA (%) | 15.6 | 17.5 | 18.1 |
| EPS (INR) | 7.2 | 9.1 | 11.2 |
| EPS Gr. (%) | 6.3 | 26.8 | 22.8 |
| BV/Sh. (INR) | 62.9 | 67.1 | 73.3 |
| Ratios | | | |
| Net D/E | 0.3 | 0.2 | 0.1 |
| RoE (%) | 11.9 | 14.1 | 16.0 |
| RoCE (%) | 11.2 | 12.5 | 14.4 |
| Payout (%) | 59.9 | 54.7 | 44.5 |
| Valuations | | | |
| P/E (x) | 26.3 | 20.8 | 16.9 |
| EV/EBITDA (x) | 11.3 | 8.5 | 7.3 |
| Div Yield (%) | 2.3 | 2.6 | 2.6 |
| FCF Yield (%) | 3.6 | 4.9 | 7.0 |

Shareholding pattern (%)

| | Mar-23 | Dec-22 | Mar-22 |
|----------|--------|--------|--------|
| Promoter | 51.5 | 51.5 | 51.9 |
| DII | 16.3 | 15.9 | 13.9 |
| FII | 12.0 | 12.1 | 14.6 |
| Others | 20.1 | 20.4 | 19.6 |

Note: FII includes depository receipts

CMP: INR190 TP: INR225 (+18%) Buy

Operating performance continues to improve

EBITDA below our estimate

- EPLL's operating performance continued to improve with EBITDA margin expanding 80bp YoY in 4QFY23. This was driven by price hikes, better product mix and softening of raw material prices. However, it missed our estimate primarily due to lower margins in the Americas led by a one-time cost related to setting up of the Brazil plant.
- We maintain our earnings estimates for FY24/FY25 and value the stock at 20x FY25E EPS to arrive at our TP of INR225. We reiterate our BUY rating.

Revenue growth across all geographies

- Revenue grew 10% YoY to INR9.7b (est. INR9.9b), aided by broad-based growth across all regions in 4QFY23. Gross margin remained flat YoY at 54% as raw material prices stabilized during the quarter. EBITDA margin rose 80bp YoY to 15.9% (est. 16.8%) led by expansion across all the geographies except the Americas. EBITDA grew 16% YoY to INR1.55b (est. INR1.65b). Adjusted PAT jumped 73% YoY to INR843m (est. INR568m) in 4QFY23.
- Revenue from AMESA/EAP/Americas/Europe grew 8%/9%/17%/20% YoY to INR3.4b/INR2.1b/INR2.3b/INR2.5b. EBIT margin expanded 370bp/350bp/40bp YoY to 12.5%/11.6%/5.4% for AMESA/EAP/Europe, while the same for the Americas contracted 710bp to 2.6%.
- The Oral Care/Personal care segments grew 9%/12% YoY in FY23, with the share of Personal care segment standing at ~47% for FY23 v/s 46% in FY22.
- In FY23, revenue/EBITDA/Adj. PAT grew 8%/was flat/rose 6% YoY to INR36.9b/INR5.8b/INR2.3b.

Highlights from the management commentary

- **Guidance:** EPLL is targeting double-digit revenue growth in the medium term with margin improvement. Capex spends annually will be equivalent to or little lower than its depreciation amount.
- Region wise outlook: AMESA (Egypt and India) is expected to remain strong; EAP (China) is likely to rebound strongly aided by multiple government initiatives; while Europe is expected to be more unstable with inflation and Russia-Ukraine war hurting demand. The adverse impact for demand in the Americas is expected to be lesser than in Europe, albeit, inflation over the region is still high.
- Brazil project is now complete and production has commenced. Volumes will be ramped up from 1QFY24. Brazil region is expected to be both growth and margin accretive for the company.

Valuation and view

- We expect the recovery in margin witnessed in recent quarters to continue going forward led by further softening in raw material prices and price hikes across regions. Further ramp up of Brazil facility by 1QFY24 will be both growth and margin accretive for the company.
- We expect a revenue/EBITDA/adjusted PAT CAGR of 13%/21%/25% over FY23-25.
- We maintain our earnings estimates for FY24/FY25 and value the stock at 20x FY25E EPS to arrive at our TP of INR225. We reiterate our BUY rating.

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Research Analyst: Meet Jain (Meet.Jain@ MotilalOswal.com) / Omkar Shintre (Omkar.Shintre@MotilalOswal.com)

Consolidated - Quarterly Earnings Model (INR m)

| Y/E March | | FY | 22 | | | FY | 23 | | FY22 | FY23 | FY23E | Var |
|---|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|-------|-----|
| | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | | | 4Q | % |
| Gross Sales | 7,991 | 8,701 | 8,834 | 8,802 | 8,318 | 9,481 | 9,449 | 9,693 | 34,328 | 36,941 | 9,857 | -2 |
| YoY Change (%) | 7.8 | 13.0 | 14.9 | 8.6 | 4.1 | 9.0 | 7.0 | 10.1 | 11.1 | 7.6 | 12.0 | |
| Total Expenditure | 6,542 | 7,107 | 7,447 | 7,471 | 7,062 | 7,995 | 7,959 | 8,147 | 28,567 | 31,163 | 8,204 | |
| EBITDA | 1,449 | 1,594 | 1,387 | 1,331 | 1,256 | 1,486 | 1,490 | 1,546 | 5,761 | 5,778 | 1,654 | -7 |
| Margins (%) | 18.1 | 18.3 | 15.7 | 15.1 | 15.1 | 15.7 | 15.8 | 15.9 | 16.8 | 15.6 | 16.8 | |
| Depreciation | 619 | 622 | 642 | 631 | 652 | 664 | 699 | 790 | 2,514 | 2,805 | 720 | |
| Interest | 89 | 97 | 103 | 114 | 122 | 157 | 189 | 206 | 403 | 674 | 185 | |
| Other Income | 53 | 14 | 31 | 22 | 42 | 68 | 43 | 268 | 120 | 421 | 40 | |
| PBT before EO expense | 794 | 889 | 673 | 608 | 524 | 733 | 645 | 818 | 2,964 | 2,720 | 789 | |
| Extra-Ord expense | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 11 | 0 | |
| PBT | 794 | 889 | 673 | 608 | 513 | 733 | 645 | 818 | 2,964 | 2,709 | 789 | |
| Tax | 189 | 297 | 82 | 107 | 141 | 249 | 10 | -27 | 675 | 373 | 213 | |
| Rate (%) | 23.8 | 33.4 | 12.2 | 17.6 | 27.5 | 34.0 | 1.6 | -3.3 | 22.8 | 13.8 | 27.0 | |
| Minority Interest & Profit/Loss of Asso. Cos. | -26 | -85 | -20 | -14 | -38 | -22 | -7 | -2 | -145 | -69 | -8 | |
| Reported PAT | 579 | 507 | 571 | 487 | 334 | 462 | 628 | 843 | 2,144 | 2,267 | 568 | |
| Adj PAT | 579 | 507 | 571 | 487 | 345 | 462 | 628 | 843 | 2,144 | 2,278 | 568 | 49 |
| YoY Change (%) | -4.3 | -24.3 | -19.5 | -14.3 | -40.4 | -8.9 | 10.0 | 73.1 | -16.0 | 6.3 | 16.6 | |
| Margins (%) | 7.2 | 5.8 | 6.5 | 5.5 | 4.1 | 4.9 | 6.6 | 8.7 | 6.2 | 6.2 | 5.8 | |

Exhibit 1: Key performance indicators


| Y/E March | 4QFY21 | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 |
|----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Segment Revenue Gr. (%) | | | | | | | | | |
| AMESA | 28% | 29% | 19% | 36% | 14% | 13% | 17% | 9% | 8% |
| EAP | 37% | 2% | 12% | 20% | 7% | -6% | 1% | -8% | 9% |
| Americas | 2% | 9% | 22% | 9% | 12% | 20% | 20% | 19% | 17% |
| Europe | 6% | -10% | -3% | -2% | 4% | 11% | 9% | 10% | 20% |
| Segment EBIT Margin (%) | | | | | | | | | |
| AMESA | 8% | 11% | 11% | 11% | 9% | 10% | 9% | 11% | 13% |
| EAP | 12% | 17% | 17% | 17% | 8% | 13% | 17% | 16% | 12% |
| Americas | 12% | 7% | 9% | 3% | 10% | 5% | 5% | 5% | 3% |
| Europe | 9% | 6% | 4% | -1% | 5% | 2% | 3% | -2% | 5% |
| Cost Break-up | | | | | | | | | |
| RM Cost (% of sales) | 43% | 42% | 43% | 45% | 46% | 44% | 46% | 45% | 46% |
| Employee Cost (% of sales) | 19% | 19% | 19% | 19% | 18% | 20% | 18% | 19% | 18% |
| Other Cost (% of sales) | 20% | 20% | 19% | 20% | 20% | 21% | 20% | 21% | 20% |
| Gross Margins (%) | 57% | 58% | 57% | 55% | 54% | 56% | 54% | 55% | 54% |
| EBITDA Margins (%) | 17% | 18% | 18% | 16% | 15% | 15% | 16% | 16% | 16% |
| EBIT Margins (%) | 10% | 10% | 11% | 8% | 8% | 7% | 9% | 8% | 8% |

Source: Company, MOFSL

Key exhibits

Exhibit 2: Consolidated revenue trend


Exhibit 3: Consolidated EBITDA trend



Source: Company, MOFSL

Source: Company, MOFSL

Exhibit 4: Consolidated adjusted PAT trend



Source: Company, MOFSL

Exhibit 5: AMESA region

| | 4QFY21 | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Revenue (INR m) | 2,766 | 2,819 | 3,075 | 3,225 | 3,140 | 3,197 | 3,595 | 3,521 | 3,379 |
| Growth (%) | 28 | 29 | 19 | 36 | 14 | 13 | 17 | 9 | 8 |
| EBIT (INR m) | 224 | 311 | 352 | 353 | 277 | 309 | 333 | 404 | 423 |
| Margin (%) | 8 | 11 | 11 | 11 | 9 | 10 | 9 | 11 | 13 |
| Growth (%) | -7 | 94 | -8 | 12 | 24 | -1 | -5 | 14 | 53 |

Source: Company, MOFSL

Exhibit 6: EAP region

| • | | | | | | | | | |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | 4QFY21 | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 |
| Revenue (INR m) | 1,849 | 2,060 | 2,136 | 2,459 | 1,971 | 1,928 | 2,166 | 2,263 | 2,141 |
| Growth (%) | 37 | 2 | 12 | 20 | 7 | -6 | 1 | -8 | 9 |
| EBIT (INR m) | 216 | 345 | 353 | 419 | 160 | 247 | 377 | 365 | 248 |
| Margin (%) | 12 | 17 | 17 | 17 | 8 | 13 | 17 | 16 | 12 |
| Growth (%) | 45 | -21 | -11 | 9 | -26 | -28 | 7 | -13 | 55 |

Source: Company, MOFSL

Exhibit 7: The Americas region

| • | 4QFY21 | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 205722 | 40EV22 |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | 4QF121 | IUF122 | ZUFTZZ | 3UF122 | 4QF122 | 1QF123 | ZQF1Z3 | 3QFY23 | 4QFY23 |
| Revenue (INR m) | 1,749 | 1,639 | 1,860 | 1,899 | 1,964 | 1,973 | 2,226 | 2,260 | 2,299 |
| Growth (%) | 2 | 9 | 22 | 9 | 12 | 20 | 20 | 19 | 17 |
| EBIT (INR m) | 202 | 119 | 168 | 53 | 189 | 105 | 106 | 109 | 59 |
| Margin (%) | 12 | 7 | 9 | 3 | 10 | 5 | 5 | 5 | 3 |
| Growth (%) | -32 | -23 | 8 | -74 | -6 | -12 | -37 | 106 | -69 |

Source: Company, MOFSL

Exhibit 8: Europe region

| | 4QFY21 | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Revenue (INR m) | 2,002 | 1,784 | 1,882 | 1,732 | 2,086 | 1,972 | 2,050 | 1,911 | 2,502 |
| Growth (%) | 6 | -10 | -3 | -2 | 4 | 11 | 9 | 10 | 20 |
| EBIT (INR m) | 189 | 99 | 75 | -22 | 104 | 34 | 70 | -36 | 134 |
| Margin (%) | 9 | 6 | 4 | -1 | 5 | 2 | 3 | -2 | 5 |
| Growth (%) | 40 | -45 | -53 | -122 | -45 | -66 | -7 | 64 | 29 |

Source: Company, MOFSL



Highlights from the management commentary Operating performance

- Gross profit for the quarter was adversely impacted because of a change in the mix of business.
- Input cost volatility is reduced and it is now range bound. Freight cost is softening; however, power cost has increased YoY in Europe and in some of the plants in India.
- The company is constantly following up with customers for price hikes wherever there is a need to increase prices.
- Margin in the Americas was hit by a one-off due to build-up of inventory during the Covid period.
- The company is committed to continuous margin improvement in the longer run. The comprehensive cost efficiency program has yielded good results.
- Other income in 4QFY23 included government grant that was related to import of machine by the company. This will continue to recur as and when EPLL incurs capital expenditure.

Outlook

- Inflation and recessionary fears in western economy have made demand less predictable. However, management expects to continue to deliver double-digit revenue growth in FY24
- It expects to ramp up volume in Brazil facility and expand customer base in Brazil
- It has continued focus on (i) margin improvement through mix and cost efficiency, (ii) efficient capital allocation, and (iii) manufacturing location optimization
- Management remains cautiously optimistic on its guidance of double-digit growth with margin improvement in the longer run.
- EPL expects capex to be in-line with depreciation or little lower than that for FY24.
- Tax rate is expected to be in range of ~26-28% going ahead.
- EPLL is good on the borrowing level based on multiple leverage ratios and can leverage further to achieve business growth.

MOTILAL OSWAL EPL

Category wise segmentation

- Personal care rose 12% YoY, while Oral care grew 9% YoY for FY23
- Personal care is growing faster than oral care and management expects this trajectory to continue going ahead. Accordingly, contribution of personal care to total revenue is expected to inch up from current levels
- Management expects growth of ~8-9% in oral care segment.

Brazil facility

- EPLL has invested ~USD20m for the Brazil facility and has completed the facility in record time
- Commercial production in the facility has started and management expects the facility to ramp up production from 1QFY24 onwards.
- EPLL has started the facility because of a request from anchor customer and first priority of company will be to supply to this anchor customer. Thereafter, it will look forward towards supplying to other customers as well
- Management expects this project to drive growth going ahead and will be margin accretive for the business from the first year itself.

Recyclable tubes (Sustainability)

- Recyclable tubes have jumped ~2.5x YoY and accounted for ~10% of total volume in FY23. Management aims to double the contribution in FY24.
- The company is one of the global leaders in terms of supply of recyclable tubes. It is implementing provisions for manufacturing of recyclable tubes in almost every facility.
- Management believes this will help company gain market share going ahead
- It is trying to make sustainable tubes with less plastic by reducing thickness and is aiming to increase barrier property so that the tubes will be more stable
- About 50% of the machines of the company are capable for producing fully recyclable tubes.

Geographical performance and outlook

- **AMESA** grew by only 7% due to devaluation of Egyptian pound while it rose 15% on constant currency basis. Management expects AMESA to continue with its strong growth going ahead. Egypt is a good performing business for the company. However, it is hit by adverse currency movements and inflation.
- EAP bounced back during the year. Management expects China to recover as Chinese government is taking a lot of efforts to revive the economy.
- The western economy is expected to be more unstable with Inflation and Russia-Ukraine war impacting the demand adversely in **Europe**.
- The adverse impact for demand in the **Americas** is expected to be lesser than Europe. However, inflation over the region is still high.

Other highlights

■ EPLL received **Gold Certificate** from EcoVadis in May'23. It received an overall score of 70 out of 100, being placed in the 94th percentile and among the top 5% on sustainable practices. EPLL was among the 90,000 odd companies across 160 countries assessed by EcoVadis. This is an improvement from EcoVadis Silver Medal, which the company received in 2022 with a score of 65.


MOTILAL OSWAL EPL

- Company is actively looking for opportunities and is also open for inorganic growth through M&A.
- EPLL has enough capacity to cater to any supply growth in their existing regions. However, it is open for any Greenfield expansion in virgin regions if anchor customers ask them.

Valuation and view

- We expect the recovery in margin witnessed in recent quarters to continue going forward led by further softening in raw material prices and price hikes across regions. Further ramp up of Brazil facility by 1QFY24 will be both growth and margin accretive for the company.
- We forecast a revenue/EBITDA/adjusted PAT CAGR of 13%/21%/25% during FY23-25.
- We maintain our earnings estimates for FY24/FY25 and value the stock at 20x
 FY25E EPS to arrive at our TP of INR225. We reiterate our BUY rating.

Exhibit 9: One-year forward P/E



Source: MOSL

Exhibit 10: Changes to our estimates

| | Old | | Nev | N | Char | nge |
|----------|--------|--------|--------|--------|-------|-------|
| (INR m) | FY24E | FY25E | FY24E | FY24E | FY24E | FY25E |
| Revenue | 42,925 | 46,303 | 43,052 | 46,874 | 0% | 1% |
| EBITDA | 7,508 | 8,541 | 7,523 | 8,505 | 0% | 0% |
| Adj. PAT | 2,932 | 3,606 | 2,889 | 3,548 | -1% | -2% |

Source: Company, MOFSL

Financials and valuations

| Consolidated - Income Statement | | | | | | | | | (INR m) |
|--|------------------|---------------------|------------------|---------------------|---------------|----------------------|------------------|------------------|---------------------|
| Y/E March | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24E | FY25E |
| Total Income from Operations | 23,023 | 24,239 | 27,069 | 27,614 | 30,916 | 34,328 | 36,941 | 43,052 | 46,874 |
| Change (%) | 8.2 | 5.3 | 11.7 | 2.0 | 12.0 | 11.0 | 7.6 | 16.5 | 8.9 |
| Raw material cost | 10,079 | 10,366 | 11,648 | 11,581 | 12,934 | 15,176 | 16,738 | 18,943 | 20,156 |
| Employees Cost | 4,052 | 4,338 | 5,006 | 5,311 | 6,064 | 6,500 | 6,895 | 7,749 | 8,437 |
| Other Expenses | 4,673 | 4,886 | 5,424 | 5,147 | 5,807 | 6,891 | 7,530 | 8,836 | 9,776 |
| Total Expenditure | 18,804 | 19,590 | 22,078 | 22,039 | 24,805 | 28,567 | 31,163 | 35,528 | 38,369 |
| % of Sales | 81.7 | 80.8 | 81.6 | 79.8 | 80.2 | 83.2 | 84.4 | 82.5 | 81.9 |
| EBITDA | 4,219 | 4,649 | 4,991 | 5,575 | 6,111 | 5,761 | 5,778 | 7,523 | 8,505 |
| Margin (%) | 18.3 | 19.2 | 18.4 | 20.2 | 19.8 | 16.8 | 15.6 | 17.5 | 18.1 |
| Depreciation | 1,415 | 1,671 | 1,861 | 2,298 | 2,346 | 2,514 | 2,805 | 3,126 | 3,369 |
| EBIT | 2,804 | 2,978 | 3,130 | 3,277 | 3,765 | 3,247 | 2,973 | 4,398 | 5,136 |
| Int. and Finance Charges | 581 | 550 | 613 | 556 | 429 | 403 | 674 | 683 | 540 |
| Other Income | 353 | 264 | 285 | 133 | 145 | 120 | 421 | 344 | 375 |
| PBT bef. EO Exp. | 2,576 | 2,691 | 2,802 | 2,854 | 3,481 | 2,964 | 2,720 | 4,059 | 4,971 |
| EO Items | 157 | -50 | 31 | -94 | -161 | 0 | -11 | 0 | 0 |
| PBT after EO Exp. | 2,732 | 2,642 | 2,833 | 2,760 | 3,320 | 2,964 | 2,709 | 4,059 | 4,971 |
| Total Tax | 787 | 889 | 932 | 638 | 868 | 675 | 373 | 1,096 | 1,342 |
| Tax Rate (%) | 28.8 | 33.7 | 32.9 | 23.1 | 26.1 | 22.8 | 13.8 | 27.0 | 27.0 |
| Profit/loss from associates | 10.5 | -10.4 | 53.2 | -6.0 | -9.0 | -76 | -29 | -30 | -32 |
| Minority Interest | 53 | 26 | 29 | 43 | 52 | 69 | 40 | 44 | 48 |
| Reported PAT | 1,903 | 1,716 | 1,925 | 2,073 | 2,391 | 2,144 | 2,267 | 2,889 | 3,548 |
| Adjusted PAT | 1,747 | 1,766 | 1,895 | 2,167 | 2,552 | 2,144 | 2,278 | 2,889 | 3,548 |
| Change (%) | 4.1 | 1.1 | 7.3 | 14.4 | 17.8 | -16.0 | 6.3 | 26.8 | 22.8 |
| Margin (%) | 7.6 | 7.3 | 7.0 | 7.8 | 8.3 | 6.2 | 6.2 | 6.7 | 7.6 |
| Consolidated - Balance Sheet Y/E March | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24E | (INR m) FY25E |
| · | 314 | 315 | 631 | 631 | 631 | 632 | 636 | 636 | 636 |
| Equity Share Capital Total Reserves | 10,076 | 12,191 | 13,249 | 14,695 | 16,350 | 17,613 | 19,256 | 20,565 | 22,533 |
| Net Worth | 10,390 | | | | | | | | |
| | 10,390 57 | 12,506 43 | 13,880 52 | 15,326 86 | 16,981 | 18,245 336 | 19,892 36 | 21,201 36 | 23,169 36 |
| Minority Interest Total Loans | 7,924 | 7,299 | 6,313 | 6,432 | 5,536 | 6,572 | 7,686 | 6,686 | |
| Deferred Tax Liabilities | 317 | 357 | 510 | 475 | 543 | 619 | 632 | 632 | 4,686 632 |
| Capital Employed | 18,688 | 20,204 | 20,754 | 22,319 | 23,393 | 25,772 | 28,246 | 28,555 | 28,523 |
| Gross Block | 15,637 | 17,691 | 20,734 | 22,434 | 25,500 | 27,236 | 32,147 | 35,077 | 37,377 |
| Less: Accum. Deprn. | 3,984 | 5,992 | 7,564 | 9,862 | 12,208 | 14,722 | 17,527 | 20,652 | 24,022 |
| Net Fixed Assets | 11,652 | 11,699 | 12,931 | 12,572 | 13,292 | 12,514 | 14,620 | 14,424 | 13,355 |
| Goodwill on Consolidation | 142 | 142 | 142 | 142 | 1,159 | 1,159 | 1,159 | 1,159 | 1,159 |
| Capital WIP | 193 | 417 | 413 | 352 | 273 | 1,466 | 1,780 | 1,150 | 1,150 |
| Total Investments | 153 | 131 | 168 | 160 | 149 | 72 | 193 | 193 | 1,130 |
| Current Investments | 0 | 0 | 0 | 0 | 0 | 0 | 150 | 150 | 150 |
| Curr. Assets, Loans&Adv. | 10,254 | 12,032 | 11,547 | 14,833 | 15,241 | 17,715 | 18,552 | 20,674 | 22,324 |
| Inventory | 2,460 | 2,864 | 3,234 | 3,692 | 4,149 | 5,941 | 6,079 | 6,814 | 7,043 |
| Account Receivables | 3,766 | 4,590 | 4,934 | 4,903 | 5,891 | 6,367 | 6,430 | 7,549 | 8,219 |
| Cash and Bank Balance | 1,028 | 1,735 | 1,344 | 3,715 | 2,414 | 1,927 | 2,444 | 2,437 | 2,843 |
| Loans and Advances | 3,000 | 2,843 | 2,035 | 2,523 | 2,787 | 3,480 | 3,599 | 3,875 | 4,219 |
| Curr. Liability & Prov. | 3,707 | 4,217 | 4,447 | 5,740 | 6,721 | 7,154 | 8,058 | 9,045 | 9,658 |
| Account Payables | 1,473 | 1,884 | 2,065 | 3,538 | 4,222 | 4,547 | 4,999 | 5,646 | 6,097 |
| Other Current Liabilities | 1,473 | 2,037 | 2,003 | 1,942 | 2,163 | 2,268 | 2,728 | 3,014 | 3,141 |
| Provisions | 400 | 2,037 | 269 | 260 | 336 | 339 | 331 | 386 | 420 |
| Net Current Assets | 6,547 | 7,815 | 7,100 | 9,093 | 8, 520 | 10,561 | 10,494 | 11,629 | 12,666 |
| Misc Expenditure | 0,547 | 0 | 7,100 | 0 | 8,520 | 10,361 | 10,494 | 0 | 12,666 |
| Appl. of Funds | 18,688 | 20,204 | 20,754 | 22,319 | 23,393 | 25,772 | 28,246 | 28,555 | 28,523 |
| תאאוי מו ו מוומס | 10,000 | 20,204 | 20,734 | 22,313 | 23,333 | 23,112 | 20,240 | 20,333 | 20,32 |

Financials and valuations

| Ratios | | | | | | | | | |
|------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------------|---------|
| Y/E March | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24E | FY25E |
| Basic (INR) | | 1120 | 1123 | | | | 1123 | | 11232 |
| EPS | 5.5 | 5.6 | 6.0 | 6.9 | 8.1 | 6.8 | 7.2 | 9.1 | 11.2 |
| Cash EPS | 10.0 | 10.9 | 11.9 | 14.1 | 15.5 | 14.7 | 16.1 | 19.0 | 21.9 |
| BV/Share | 32.9 | 39.6 | 43.9 | 48.5 | 53.7 | 57.7 | 62.9 | 67.1 | 73.3 |
| DPS | 1.1 | 1.2 | 1.2 | 3.3 | 4.1 | 4.2 | 4.3 | 5.0 | 5.0 |
| Payout (%) | 21.8 | 26.4 | 23.6 | 56.7 | 54.2 | 61.9 | 59.9 | 54.7 | 44.5 |
| Valuation (x) | | | | | | 02.0 | 00.0 | <u> </u> | |
| P/E | 34.3 | 34.0 | 31.6 | 27.7 | 23.5 | 28.0 | 26.3 | 20.8 | 16.9 |
| Cash P/E | 19.0 | 17.4 | 16.0 | 13.4 | 12.2 | 12.9 | 11.8 | 10.0 | 8.7 |
| P/BV | 5.8 | 4.8 | 4.3 | 3.9 | 3.5 | 3.3 | 3.0 | 2.8 | 2.6 |
| EV/Sales | 2.9 | 2.7 | 2.4 | 2.3 | 2.1 | 1.9 | 1.8 | 1.5 | 1.3 |
| EV/EBITDA | 15.9 | 14.1 | 13.0 | 11.3 | 10.4 | 11.3 | 11.3 | 8.5 | 7.3 |
| Dividend Yield (%) | 0.6 | 0.6 | 0.6 | 1.7 | 2.2 | 2.2 | 2.3 | 2.6 | 2.6 |
| FCF per share | 5.1 | 6.5 | 1.8 | 9.0 | 5.8 | 1.4 | 6.8 | 9.4 | 13.3 |
| Return Ratios (%) | | | | | | | | - | |
| RoE | 17.4 | 15.4 | 14.4 | 14.8 | 15.8 | 12.2 | 11.9 | 14.1 | 16.0 |
| RoCE | 12.9 | 11.3 | 11.5 | 12.5 | 13.0 | 11.0 | 11.2 | 12.5 | 14.4 |
| RoIC | 12.2 | 11.2 | 11.4 | 13.6 | 14.4 | 11.7 | 11.1 | 13.2 | 15.3 |
| Working Capital Ratios | | | | | | | | | |
| Fixed Asset Turnover (x) | 1.5 | 1.4 | 1.3 | 1.2 | 1.2 | 1.3 | 1.1 | 1.2 | 1.3 |
| Asset Turnover (x) | 1.2 | 1.2 | 1.3 | 1.2 | 1.3 | 1.3 | 1.3 | 1.5 | 1.6 |
| Inventory (Days) | 39 | 43 | 44 | 49 | 49 | 63 | 60 | 58 | 55 |
| Debtor (Days) | 60 | 69 | 67 | 65 | 70 | 68 | 64 | 64 | 64 |
| Creditor (Days) | 23 | 28 | 28 | 47 | 50 | 48 | 49 | 48 | 47 |
| Leverage Ratio (x) | | | | | | | | | |
| Current Ratio | 2.8 | 2.9 | 2.6 | 2.6 | 2.3 | 2.5 | 2.3 | 2.3 | 2.3 |
| Interest Cover Ratio | 4.8 | 5.4 | 5.1 | 5.9 | 8.8 | 8.1 | 4.4 | 6.4 | 9.5 |
| Net Debt/Equity | 0.7 | 0.4 | 0.4 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.1 |
| , | | | | | | | | | |
| Consolidated - Cash Flow Statement | | | | | | | | | (INR m) |
| Y/E March | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24E | FY25E |
| OP/(Loss) before Tax | 2,743 | 2,631 | 2,886 | 2,854 | 3,311 | 2,888 | 2,680 | 4,059 | 4,971 |
| Depreciation | 1,415 | 1,671 | 1,861 | 2,298 | 2,346 | 2,514 | 2,805 | 3,126 | 3,369 |
| Interest & Finance Charges | 284 | 277 | 380 | 423 | 381 | 355 | 674 | 338 | 165 |
| Direct Taxes Paid | -764 | -816 | -901 | -638 | -866 | -776 | -449 | -1,096 | -1,342 |
| (Inc)/Dec in WC | 494 | -488 | -404 | -127 | -380 | -2,217 | 136 | -1,142 | -631 |
| CF from Operations | 4,172 | 3,276 | 3,821 | 4,811 | 4,792 | 2,764 | 5,846 | 5,285 | 6,532 |
| Others | -485 | 159 | -257 | -100 | 432 | 353 | 172 | -30 | -32 |
| CF from Operating incl EO | 3,687 | 3,435 | 3,564 | 4,711 | 5,224 | 3,117 | 6,018 | 5,255 | 6,500 |
| (Inc)/Dec in FA | -2,069 | -1,375 | -3,003 | -1,878 | -3,396 | -2,668 | -3,871 | -2,300 | -2,300 |
| Free Cash Flow | 1,618 | 2,060 | 561 | 2,833 | 1,828 | 449 | 2,147 | 2,955 | 4,200 |
| (Pur)/Sale of Investments | 98 | 1 | 2 | 8 | 5 | 4 | -147 | 0 | 0 |
| Others | -769 | 184 | 1,122 | 680 | 586 | 22 | 126 | 344 | 375 |
| CF from Investments | -2,740 | -1,189 | -1,879 | -1,190 | -2,805 | -2,642 | -3,892 | -1,956 | -1,925 |
| Issue of Shares | 7 | 510 | 53 | 0 | 7 | 50 | 0 | 0 | 0 |
| Inc/(Dec) in Debt | 546 | -1,199 | -1,028 | 119 | -1,219 | 1,031 | 1,386 | -1,000 | -2,000 |
| Interest Paid | -392 | -372 | -485 | -556 | -321 | -278 | -575 | -683 | -540 |
| Dividend Paid | -414 | -478 | -478 | -1,176 | -1,341 | -1,380 | -1,362 | -1,580 | -1,580 |
| Others | -508 | -1 | -138 | 469 | -317 | -377 | -832 | -44 | -48 |
| CF from Fin. Activity | -762 | -1,539 | -2,076 | -1,143 | -3,191 | -954 | -1,383 | -3,307 | -4,169 |
| Inc/Dec of Cash | 184 | 706 | -391 | 2,377 | -772 | -479 | 743 | -7 | 406 |
| Opening Balance | 844 | 1,028 | 1,735 | 1,344 | 3,116 | 2,414 | 1,927 | 2,444 | 2,437 |
| Closing Balance | 1,028 | 1,735 | 1,344 | 3,715 | 2,414 | 1,927 | 2,444 | 2,437 | 2,843 |

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

| Explanation of Investment Rating | | | | | |
|----------------------------------|--|--|--|--|--|
| Investment Rating | Expected return (over 12-month) | | | | |
| BUY | >=15% | | | | |
| SELL | <-10% | | | | |
| NEUTRAL | < - 10 % to 15% | | | | |
| UNDER REVIEW | Rating may undergo a change | | | | |
| NOT RATED | We have forward looking estimates for the stock but we refrain from assigning recommendation | | | | |

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at

20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the

website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx
A graph of daily closing prices of securities is available at www.nseindia.com, https://www.nseindia.com, https://www.nseindia.com, www.nseindia.com, www.nseindia.com, www.nseindia.com, www.nseindia.com, www.nseindia.com, <a href="https://www.nsein research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company. MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

20 May 2023

MOTILAL OSWAL EPL

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No:022-40548085.

| Glievalice Neuressai Cell. | | | |
|----------------------------|-----------------------------|------------------------------|--|
| Contact Person | Contact No. | Email ID | |
| Ms. Hemangi Date | 022 40548000 / 022 67490600 | query@motilaloswal.com | |
| Ms. Kumud Upadhyay | 022 40548082 | servicehead@motilaloswal.com | |
| Mr. Ajay Menon | 022 40548083 | am@motilaloswal.com | |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.